AbbVie Stock Forecast, Price & News

$115.08
0.00 (0.00 %)
(As of 08/5/2021 01:34 PM ET)
Add
Compare
Today's Range
$114.45
$115.56
50-Day Range
$111.40
$118.87
52-Week Range
$79.11
$119.15
Volume157,504 shs
Average Volume5.86 million shs
Market Capitalization$203.37 billion
P/E Ratio31.02
Dividend Yield4.47%
Beta0.82
30 days | 90 days | 365 days | Advanced Chart
Receive ABBV News and Ratings via Email

Sign-up to receive the latest news and ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter.


AbbVie logo

About AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

3.17 out of 5 stars

Medical Sector

5th out of 1,311 stocks

Pharmaceutical Preparations Industry

3rd out of 647 stocks

Analyst Opinion: 2.4Community Rank: 4.9Dividend Strength: 5.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











AbbVie (NYSE:ABBV) Frequently Asked Questions

Is AbbVie a buy right now?

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AbbVie stock.
View analyst ratings for AbbVie
or view top-rated stocks.

What stocks does MarketBeat like better than AbbVie?

Wall Street analysts have given AbbVie a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but AbbVie wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is AbbVie's next earnings date?

AbbVie is scheduled to release its next quarterly earnings announcement on Friday, October 29th 2021.
View our earnings forecast for AbbVie
.

How were AbbVie's earnings last quarter?

AbbVie Inc. (NYSE:ABBV) released its quarterly earnings data on Thursday, July, 29th. The company reported $3.11 EPS for the quarter, topping the consensus estimate of $3.09 by $0.02. The business earned $13.96 billion during the quarter, compared to analyst estimates of $13.64 billion. AbbVie had a net margin of 12.40% and a trailing twelve-month return on equity of 154.24%. The company's revenue was up 33.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.34 earnings per share.
View AbbVie's earnings history
.

How has AbbVie's stock price been impacted by COVID-19 (Coronavirus)?

AbbVie's stock was trading at $84.85 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ABBV stock has increased by 35.7% and is now trading at $115.10.
View which stocks have been most impacted by COVID-19
.

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie announced a quarterly dividend on Thursday, June 17th. Investors of record on Thursday, July 15th will be paid a dividend of $1.30 per share on Monday, August 16th. This represents a $5.20 annualized dividend and a dividend yield of 4.52%. The ex-dividend date is Wednesday, July 14th.
View AbbVie's dividend history
.

Is AbbVie a good dividend stock?

AbbVie pays an annual dividend of $5.20 per share and currently has a dividend yield of 4.47%. ABBV has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. AbbVie has been increasing its dividend for 49 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of AbbVie is 49.24%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, AbbVie will have a dividend payout ratio of 36.98% next year. This indicates that AbbVie will be able to sustain or increase its dividend.
View AbbVie's dividend history.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie issued an update on its FY21 earnings guidance on Friday, July, 30th. The company provided earnings per share (EPS) guidance of $12.52-12.62 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $12.58.

What price target have analysts set for ABBV?

16 brokers have issued twelve-month target prices for AbbVie's shares. Their forecasts range from $98.00 to $145.00. On average, they anticipate AbbVie's stock price to reach $122.58 in the next twelve months. This suggests a possible upside of 6.5% from the stock's current price.
View analysts' price targets for AbbVie
or view top-rated stocks among Wall Street analysts.

Who are AbbVie's key executives?

AbbVie's management team includes the following people:
  • Richard A. Gonzalez, Chairman & Chief Executive Officer
  • Michael E. Severino, Vice Chairman-Management Board & President
  • Azita Saleki-Gerhardt, Executive Vice President-Operations
  • Robert A. Michael, Chief Financial Officer & Executive Vice President
  • Thomas J. Hudson, Chief Scientific Officer, Senior VP-R&D

What is Richard A. Gonzalez's approval rating as AbbVie's CEO?

580 employees have rated AbbVie CEO Richard A. Gonzalez on Glassdoor.com. Richard A. Gonzalez has an approval rating of 88% among AbbVie's employees.

Who are some of AbbVie's key competitors?

What other stocks do shareholders of AbbVie own?

What is AbbVie's stock symbol?

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

Who are AbbVie's major shareholders?

AbbVie's stock is owned by a number of institutional and retail investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (0.40%), New York State Common Retirement Fund (0.21%), LSV Asset Management (0.18%), Envestnet Asset Management Inc. (0.17%), DekaBank Deutsche Girozentrale (0.16%) and Alliancebernstein L.P. (0.14%). Company insiders that own AbbVie stock include Brian L Durkin, Carlos Alban, Carrie C Strom, Edward J Rapp, Elaine K Sorg, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Nicholas Donoghoe, Richard A Gonzalez and Timothy J Richmond.
View institutional ownership trends for AbbVie
.

Which institutional investors are selling AbbVie stock?

ABBV stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Teacher Retirement System of Texas, GSB Wealth Management LLC, Oregon Public Employees Retirement Fund, Russell Investments Group Ltd., Alliancebernstein L.P., Artemis Investment Management LLP, and State of Michigan Retirement System. Company insiders that have sold AbbVie company stock in the last year include Carrie C Strom, Elaine K Sorg, Jeffrey Ryan Stewart, Richard A Gonzalez, and Timothy J Richmond.
View insider buying and selling activity for AbbVie
or view top insider-selling stocks.

Which institutional investors are buying AbbVie stock?

ABBV stock was purchased by a variety of institutional investors in the last quarter, including Mn Services Vermogensbeheer B.V., Victory Capital Management Inc., MUFG Securities EMEA plc, Clark Capital Management Group Inc., DekaBank Deutsche Girozentrale, Calamos Advisors LLC, OLD Republic International Corp, and Cutler Group LP. Company insiders that have bought AbbVie stock in the last two years include Brian L Durkin, Edward J Rapp, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, and Nicholas Donoghoe.
View insider buying and selling activity for AbbVie
or or view top insider-buying stocks.

How do I buy shares of AbbVie?

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AbbVie's stock price today?

One share of ABBV stock can currently be purchased for approximately $115.10.

How much money does AbbVie make?

AbbVie has a market capitalization of $203.40 billion and generates $45.80 billion in revenue each year. The company earns $4.62 billion in net income (profit) each year or $10.56 on an earnings per share basis.

How many employees does AbbVie have?

AbbVie employs 47,000 workers across the globe.

Does AbbVie have any subsidiaries?

The following companies are subsidiares of AbbVie: AbbVie (Gibraltar) Holdings Limited, AbbVie (Gibraltar) Holdings Limited Luxembourg S.C.S., AbbVie (Gibraltar) Limited, AbbVie (Pty) Ltd., AbbVie A/S, AbbVie AB, AbbVie AG, AbbVie AS, AbbVie Australasia Holdings Limited, AbbVie B.V., AbbVie Bahamas Ltd., AbbVie Biofarmacevtska družba d.o.o., AbbVie Biopharmaceuticals GmbH, AbbVie Biopharmaceuticals LLC, AbbVie Biopharmaceuticals Ltd., AbbVie Bioresearch Center Inc., AbbVie Biotech Ventures Inc., AbbVie Biotechnology GmbH, AbbVie Biotechnology Ltd, AbbVie Biotherapeutics Inc., AbbVie Biotherapeutics Limited, AbbVie Central Finance B.V., AbbVie Corp, AbbVie Corporation, AbbVie Deutschland GmbH & Co. KG, AbbVie EOOD, AbbVie Endocrine Inc., AbbVie Endocrinology Inc., AbbVie Farmacéuticos S.A. de C.V., AbbVie Farmacêutica Ltda., AbbVie Finance B.V., AbbVie Finance Corporation, AbbVie Finance LLC, AbbVie GK, AbbVie GmbH, AbbVie Holdings Corporation, AbbVie Holdings Inc., AbbVie Holdings KK, AbbVie Holdings SAS, AbbVie Holdings Unlimited, AbbVie Holdings s.r.o., AbbVie International S.à r.l., AbbVie Investments Limited, AbbVie Investments S.à r.l., AbbVie Ireland Holdings Limited, AbbVie Ireland NL B.V., AbbVie Ireland Unlimited Company, AbbVie Japan Holdings B.V., AbbVie Kft., AbbVie Komplementär GmbH, AbbVie L.L.C., AbbVie L.da, AbbVie Limited, AbbVie Limited Liability Company, AbbVie Logistics B.V., AbbVie Ltd, AbbVie Ltd., AbbVie Manufacturing Management Limited, AbbVie Nederland Holdings B.V., AbbVie Operations Singapore Pte. Ltd., AbbVie Overseas S.à r.l., AbbVie Oy, AbbVie Participações Ltda., AbbVie Pharmaceutical Trading (Shanghai) Co. Ltd., AbbVie Pharmaceuticals B.V., AbbVie Pharmaceuticals GmbH, AbbVie Pharmaceuticals LLC, AbbVie Pharmaceuticals SCA., AbbVie Pharmaceuticals Societe Anonyme, AbbVie Polska Sp. z o.o., AbbVie Productos Farmacéuticos Limitada, AbbVie Products LLC, AbbVie Promoção L.da, AbbVie Pte. Ltd., AbbVie Pty Ltd, AbbVie Purchasing LLC, AbbVie Real Estate Management GmbH, AbbVie Research B.V., AbbVie Resources Inc., AbbVie Resources International Inc., AbbVie Respiratory LLC, AbbVie S. de R.L., AbbVie S.A., AbbVie S.A., AbbVie S.A.S., AbbVie S.R.L., AbbVie S.r.l., AbbVie S.à r.l., AbbVie SA, AbbVie SAS, AbbVie SIA, AbbVie Sarl, AbbVie Sdn. Bhd., AbbVie Sp. z o.o., AbbVie Spain S.L., AbbVie Stemcentrx LLC, AbbVie Trading S.R.L., AbbVie Trustee Company Limited, AbbVie Tıbbi İlaçlar Sanayi ve Ticaret Limited Şirketi, AbbVie UAB, AbbVie UK Biopharmaceuticals Ltd, AbbVie UK Holdco Limited, AbbVie UK Ltd, AbbVie US Holdings LLC, AbbVie US LLC, AbbVie Venezuela B.V., AbbVie Venezuela Holdings B.V., AbbVie Ventures LLC, AbbVie d.o.o., AbbVie s.r.o., Aeropharm Technology LLC, Allergan, BioDisplay Technologies Inc., Fournier Laboratories Ireland Ltd., Fremont Holding L.L.C., Fundación AbbVie, IEP Pharmaceutical Devices LLC, ImmuVen, KOS Pharmaceuticals Inc., Knoll LLC, Knoll Pharmaceutical Company, Life Properties Inc., Mavupharma, Organics L.L.C., Pharmacyclics (Europe) Limited, Pharmacyclics (Shanghai) Management Consulting Services Limited, Pharmacyclics Cayman Ltd., Pharmacyclics Inc, Pharmacyclics LLC, Pharmacyclics Switzerland GmbH, Rowell Laboratories Inc., S.C. AbbVie S.R.L., Sapphire Merger Sub Inc., Stem CentRx, Stemcentrx Cayman Ltd., Suffolk Merger Sub Inc., and Unimed Pharmaceuticals LLC.

When was AbbVie founded?

AbbVie was founded in 2013.

What is AbbVie's official website?

The official website for AbbVie is www.abbvie.com.

Where are AbbVie's headquarters?

AbbVie is headquartered at 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064.

How can I contact AbbVie?

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at (847) 932-7900.


This page was last updated on 8/5/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.